Abnormalities in HER2 gene found in wide variety of advanced cancers
(Thomas Jefferson University) The HER2 growth-factor gene is known to be over-active in breast and gastro-esophageal cancers. But now, irregularities in the genes' expression -- among them mutations, amplifications, substitutions, and translocations -- have been found in 14 different advanced solid tumors. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 2, 2013 Category: Global & Universal Source Type: news

PIK3CA Mutations Negatively Affect Survival in Trastuzumab-Treated HER2-Positive Breast Cancer
A study confirmed that PIK3CA mutations negatively affect survival in patients with HER2-positive breast cancer treated with the anti-HER2 therapy trastuzumab. (Source: Cancer Network)
Source: Cancer Network - May 6, 2013 Category: Cancer & Oncology Source Type: news

HER2-Targeted Therapies Could Benefit Lung Cancer Patients With HER2 Mutations
A new study shows that drugs targeting HER2 might provide good results in the rare non-small-cell lung cancer (NSCLC) patients with HER2 mutations. (Source: Cancer Network)
Source: Cancer Network - May 1, 2013 Category: Cancer & Oncology Source Type: news

Patients With Lung Cancer Who Carry Specific HER2 Mutations May Benefit From Certain Anti-HER2 Treatments
New results from a retrospective study conducted in Europe suggest that anti-HER2 treatments, like the widely used breast cancer agent trastuzumab (Herceptin), have anti-cancer effects in a small subset of patients with advanced non-small cell lung cancer (NSCLC) harboring specific HER2 protein mutations. Although genetic changes cause tumor cells to make too much of the HER2 protein in up to 20% of lung cancers, mutations in the HER2 gene occur in only 1-2% of lung cancers... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - April 24, 2013 Category: Consumer Health News Tags: Lung Cancer Source Type: news

HER2-Targeted Drugs Useful in Some Lung Cancer PatientsHER2-Targeted Drugs Useful in Some Lung Cancer Patients
Drugs such as trastuzumab have already transformed the treatment of breast cancer. New research suggests they may also be useful in lung cancer. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 24, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

HER2-Positive NSCLC Yields to Targeted Agents (CME/CE)
(MedPage Today) -- A majority of patients with HER2-positive lung cancer had objective responses or stable disease when they received anti-HER2 agents in addition to chemotherapy, a small clinical study showed. (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - April 22, 2013 Category: Primary Care Source Type: news

Tumors with ALK rearrangements can harbor more mutations
(International Association for the Study of Lung Cancer) The identification of potentially targetable kinase mutations has been an exciting advancement in lung cancer treatment. Although the mutations driving many lung carcinomas remain unknown, approximately 50 percent of lung adenocarcinoma cases harbor KRAS mutation, EGFR mutation, or ALK translocation, and an additional 5 percent or so have been shown to have mutations involving BRAF, PIK3CA, HER2, MET, MEK1, NRAS, and AKT. In the vast majority, these driver mutations are mutually exclusive. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 22, 2013 Category: Global & Universal Source Type: news

Bevacizumab No Extra Help in Metastatic Breast CancerBevacizumab No Extra Help in Metastatic Breast Cancer
In metastatic breast cancer, adding bevacizumab to first-line chemotherapy improves progression-free survival (PFS) when tumors are HER2-negative - but not, as researchers just found out, when they're HER2-positive. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 19, 2013 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Merrimack completes patient enrolment in one cohort of Phase 2 study into breast cancer agent
Biopharmaceutical company Merrimack Pharmaceuticals has completed patient enrolment in one group of a two-cohort randomised Phase 2 study of MM-121 in HER2-negative breast cancer. (Source: Drug Development Technology)
Source: Drug Development Technology - April 16, 2013 Category: Pharmaceuticals Source Type: news

Breast cancer drug receives 'breakthrough therapy' designation from FDA
An experimental drug being investigated for the treatment of advanced breast cancer by researchers from the Revlon/UCLA Women's Cancer Research Program at UCLA's Jonsson Comprehensive Cancer Center this week received "breakthrough therapy" designation from the U.S. Food and Drug Administration.   In a clinical trial, patients with advanced breast cancer that was estrogen-receptor positive (ER+) and HER2-negative (HER2-), and who were given palbociclib (PD 0332991, Pfizer Inc.) in addition to the standard anti-estrogen treatment of letrozole had significantly higher progression-free survival — the lengt...
Source: UCLA Newsroom: Health Sciences - April 13, 2013 Category: Universities & Medical Training Source Type: news

Overwhelming Evidence Adds A Major New Target In Breast Cancer: Androgens Including Testosterone
Estrogen and progesterone receptors, and the gene HER2 - these are the big three markers and/or targets in breast cancer. Evidence presented at the AACR Annual Meeting 2013 adds a fourth: androgen receptors. "This is a continuing line of work with all evidence pointing toward the addition of the androgen receptor as potential target and useful marker in all of the major subtypes of breast cancer," says Jennifer Richer, PhD, investigator at the University of Colorado Cancer Center and co-director of the CU Cancer Center Tissue Processing and Procurement Core... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - April 12, 2013 Category: Consumer Health News Tags: Breast Cancer Source Type: news

AACR: Results of THYME Trial Show the Time Is Not Right for AZD8931
The THYME trial testing AZD8931 in advanced HER2-low breast cancer failed to reach the primary endpoint of progression-free survival, according to results of the phase II trial presented at the 2013 AACR meeting in Washington, DC. (Source: Cancer Network)
Source: Cancer Network - April 11, 2013 Category: Cancer & Oncology Source Type: news

Roche Group posts strong sales growth in the first quarter
Group sales increase 6% at CER to 11.6 billion Swiss francs; Pharmaceuticals sales rise 7% to 9.2 billion Swiss francs, driven by cancer medicines and Tamiflu; Successful launches of Kadcyla and Perjeta strengthen HER2-positive breast cancer franchise; Diagnostics sales rise 1% to 2.4 billion Swiss francs; strong growth in Professional Diagnostics (+5%), decline in Diabetes Care (-5%); Full-year outlook confirmed (Source: Roche Investor Update)
Source: Roche Investor Update - April 11, 2013 Category: Pharmaceuticals Source Type: news

Roche Group posts strong sales growth in the first quarter
Group sales increase 6% at CER to 11.6 billion Swiss francs; Pharmaceuticals sales rise 7% to 9.2 billion Swiss francs, driven by cancer medicines and Tamiflu; Successful launches of Kadcyla and Perjeta strengthen HER2-positive breast cancer franchise (Source: Roche Media News)
Source: Roche Media News - April 11, 2013 Category: Pharmaceuticals Source Type: news

Mutation Status May Guide Treatment for HER2 Breast CancerMutation Status May Guide Treatment for HER2 Breast Cancer
It is likely that biomarkers will eventually help determine which therapy is best in HER2-positive disease. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 11, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Combined HER2 Targeted Therapy Without Chemotherapy Will Likely Benefit Certain Breast Cancer Patients
Is the era of targeted therapy for breast cancer at hand? It could be, said experts at the Lester and Sue Smith Breast Center at Baylor College of Medicine - at least for a certain population of women. In a report that appears online in the Journal of Clinical Oncology, the researchers have shown that a subset of breast cancer patients who have tumors overexpressing a protein called the human epidermal growth factor receptor 2 (HER-2 positive) may benefit from a combination of targeted treatments that zero in on the breast cancer cells themselves... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - April 10, 2013 Category: Consumer Health News Tags: Breast Cancer Source Type: news

AACR news: Studies show increasing evidence that androgen drives breast cancer
(University of Colorado Denver) Estrogen and progesterone receptors, and the gene HER2 -- these are the big three markers and/or targets in breast cancer. Evidence presented at the AACR Annual Meeting 2013 adds a fourth: Androgen receptors. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 10, 2013 Category: Cancer & Oncology Source Type: news

RNA-Based Determination of ESR1 and HER2 ExpressionRNA-Based Determination of ESR1 and HER2 Expression
Hormone and HER2 receptors are the most important breast cancer biomarkers, and additional objective and quantitative test methods such as mRNA-based quantitative analysis are urgently needed. Annals of Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 8, 2013 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

AACR: T-DM1 Most Effective in Breast Cancer Patients With High HER2 Expression
Researchers participating in the phase III EMILIA trial have identified tumor biomarkers that can identify patients that are more likely to benefit from T-DM1. In the trial, women whose tumors had higher HER2 expression were most likely to benefit from the therapy. (Source: Cancer Network)
Source: Cancer Network - April 8, 2013 Category: Cancer & Oncology Source Type: news

T-DM1 and the Dawn of Precision MedicineT-DM1 and the Dawn of Precision Medicine
Dr. Maurie Markman sees T-DM1, which combines antitumor activities of trastuzumab and HER2-targeted delivery of a cytotoxic agent, as an example of the precision medicine we can expect in the future. Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 20, 2013 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

HER2-Positive Breast Cancer Patients Prefer Faster Subcutaneous Administration Of Herceptin® (Trastuzumab) To IV
Further research also reveals quicker administration of Herceptin could save NHS £15m compared to current practice1 Results from the PrefHer (Patient Preference for Subcutaneous (SC) versus Intravenous (IV) Herceptin) trial show that 92% of early HER2-positive breast cancer patients favoured quicker SC administration of Herceptin compared to the standard IV infusion.1 Presented at the St. Gallen Breast Cancer Conference in Switzerland. The primary reasons for preferring SC administration given by patients in the trial were less pain/discomfort and time saving... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 19, 2013 Category: Consumer Health News Tags: Breast Cancer Source Type: news

New Treatment For Advanced HER2+ Breast Cancer Patients As Perjeta® (Pertuzumab) Gets Regulatory Green Light
Perjeta works synergistically with Herceptin® (trastuzumab) to extend survival and stall disease progression for longer than the gold standard of care[i] From now on, patients with advanced HER2-positive breast cancer could benefit from the new personalised breast cancer treatment, Perjeta - which is now authorised for use in the UK. Perjeta has been granted a licence by the European Medicines Agency (EMA), for patients with previously untreated advanced HER2-positive breast cancer in combination with the current gold standard-of-care, Herceptin and chemotherapy (docetaxel)... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 19, 2013 Category: Consumer Health News Tags: Breast Cancer Source Type: news

Breast cancer drug 'biggest boost since Herceptin'
Thousands of women with a type of advanced breast cancer could benefit from a drug described as the biggest step-change in treatment of the disease since Herceptin was introduced in 1999. (Source: Telegraph Health)
Source: Telegraph Health - March 14, 2013 Category: Consumer Health News Tags: perjeta herceptin tumour roche breast cancer HER2 Source Type: news

Roche obtains EU approval for PERJETA, a new personalised treatment for aggressive type of breast cancer
Roche today announced that the European Medicines Agency (EMA) has approved PERJETA(pertuzumab) for patients with previously untreated HER2-positive metastatic breast cancer (mBC). PERJETA is approved in combination with Herceptin (trastuzumab) and docetaxel in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease. (Source: Roche Investor Update)
Source: Roche Investor Update - March 5, 2013 Category: Pharmaceuticals Source Type: news

Roche obtains EU approval for PERJETA, a new personalised treatment for aggressive type of breast cancer
Roche today announced that the European Medicines Agency (EMA) has approved PERJETA(pertuzumab) for patients with previously untreated HER2-positive metastatic breast cancer (mBC). (Source: Roche Media News)
Source: Roche Media News - March 5, 2013 Category: Pharmaceuticals Source Type: news

Breast Cancer Stem Cells Express HER2, Even In 'Negative' Tumors, Study Finds
New research from the University of Michigan Comprehensive Cancer Center finds that the protein HER2 plays a role even in breast cancers that would traditionally be categorized as HER2-negative - and that the drug Herceptin, which targets HER2, may have an even greater role for treating breast cancer and preventing its spread. About 20 percent of women with breast cancer have tumors labeled HER2-positive... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - February 28, 2013 Category: Consumer Health News Tags: Breast Cancer Source Type: news

HER2 Therapy Useful in More Than 20% of Breast CancersHER2 Therapy Useful in More Than 20% of Breast Cancers
The finding of HER2 in the small clump of cancer stems cells that drives the growth and spread of tumors suggests a wider use for drugs such as trastuzumab. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 26, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Herceptin 'could benefit thousands more women'
The highly effective breast cancer drug Herceptin could benefit thousands more women, according to a study which suggests it could stop the disease spreading in most patients if given early enough. (Source: Telegraph Health)
Source: Telegraph Health - February 26, 2013 Category: Consumer Health News Tags: herceptin michigan university cancer research breast cancer HER2 Source Type: news

Kadcyla Wins US FDA Approval for Late-Stage Breast Cancer
Ado-trastuzumab emtansine, a HER-2 targeted antibody-drug conjugate, has been approved by the U.S. Food and Drug Administration for treatment of women with HER2-positive, late-stage metastatic breast cancer,... (Source: OncologySTAT Latest News)
Source: OncologySTAT Latest News - February 26, 2013 Category: Cancer & Oncology Source Type: news

U-M study challenges notion of using Herceptin only for HER2-positive breast cancer
(University of Michigan Health System) New research from the University of Michigan Comprehensive Cancer Center finds that the protein HER2 plays a role even in breast cancers that would traditionally be categorized as HER2-negative -- and that the drug Herceptin, which targets HER2, may have an even greater role for treating breast cancer and preventing its spread. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 26, 2013 Category: Cancer & Oncology Source Type: news

Horizon scanning: US FDA approves ado-trastuzumab emtansine or T-DM1 (KadcylaT) for HER2-positive metastatic breast cancer
Source: BioSpace Area: News The US FDA has approved the antibody-drug conjugate ado-trastuzumab emtansine or T-DM1 (KadcylaT) for the treatment of people with HER2-positive metastatic breast cancer who have received prior treatment with trastuzumab (Herceptin®) and a taxane.   KadcylaT, which is composed of the cytotoxic agent DM1 conjugated to trastuzumab, is the first antibody-drug conjugate to be approved by the FDA for the treatment of metastatic breast cancer. The approval was based on the results of the EMILIA Phase III study (n=991), which compared KadcylaT alone to lapatinib in combination with capec...
Source: NeLM - News - February 25, 2013 Category: Drugs & Pharmacology Source Type: news

Kadcyla Wins FDA Approval For HER2 Breast Cancer
A new drug will soon be available to treat HER2-positive metastatic breast cancer. Made by Genentech, it will be known as Kadcyla (ado-trastuzumab emtansine). This drug is a highly targeted ...Read Full Post (Source: About.com Breast Cancer)
Source: About.com Breast Cancer - February 25, 2013 Category: Cancer & Oncology Source Type: news

FDA approves Genentech metastatic breast cancer drug
The US Food and Drug Administration (FDA) has approved Genentech's Kadcyla (ado-trastuzumab emtansine or T-DM1) for the treatment of HER2-positive metastatic breast cancer (mBC). (Source: Drug Development Technology)
Source: Drug Development Technology - February 25, 2013 Category: Pharmaceuticals Source Type: news

New drug OKd for late-stage breast cancer
WASHINGTON, Feb. 23 (UPI) -- The U.S. Food and Drug Administration approved Kadcyla, a new drug for patients with HER2-positive, late-stage or metastatic breast cancer. (Source: Health News - UPI.com)
Source: Health News - UPI.com - February 24, 2013 Category: Consumer Health News Source Type: news

FDA OKs Genentech Breast Cancer Drug
(MedPage Today) -- A drug antibody conjugate called ado-trastuzumab emtansine (Kadcyla) received FDA approval Friday for HER2-positive, metastatic breast cancer. (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - February 23, 2013 Category: Hematology Source Type: news

FDA Approves Kadcyla for Late-Stage Breast Cancer
February 22, 2013 -- The U.S. Food and Drug Administration today approved Kadcyla (ado-trastuzumab emtansine), a new therapy for patients with HER2-positive, late-stage (metastatic) breast cancer. HER2 is a protein involved in normal cell growth.... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 22, 2013 Category: Drugs & Pharmacology Source Type: news

Kadcyla For Late-Stage Breast Cancer Approved By FDA
Kadcyla (ado-trastuzumab emtansine), a new medication for the treatment of HER2-positive, metastatic breast cancer, has been approved by the Food and Drug Administration (FDA), USA. Metastatic, also known as late-stage, means the cancer has spread to other parts of the body. HER2, a protein which drives normal cell growth, is found in larger quantities in several kinds of cancer cells (HER2-positive), including a number of breast cancers. The HER2 protein contributes to the growth and survival of cancer cells in patients with HER2-positive breast cancer... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - February 22, 2013 Category: Consumer Health News Tags: Breast Cancer Source Type: news

FDA Approves New Treatment for Metastatic HER2 Breast CancerFDA Approves New Treatment for Metastatic HER2 Breast Cancer
Trastuzumab emtansine, also known as T-DM1, provides clinicians with another treatment option for patients who progress on trastuzumab. FDA Approvals (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 22, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

FDA approves Roche's Kadcyla (trastuzumab emtansine), the first antibody-drug conjugate for treating HER2-positive metastatic breast cancer
Roche today announced that the U.S. Food and Drug Administration (FDA) has approved Kadcyla (trastuzumab emtansine or T-DM1) for the treatment of people with HER2-positive metastatic breast cancer (mBC) who have received prior treatment with Herceptin (trastuzumab) and a taxane chemotherapy. (Source: Roche Investor Update)
Source: Roche Investor Update - February 22, 2013 Category: Pharmaceuticals Source Type: news

FDA approves Roche's Kadcyla (trastuzumab emtansine), the first antibody-drug conjugate for treating HER2-positive metastatic breast cancer
New personalised medicine helped people in Phase III study live longer, compared to standard treatment (Source: Roche Media News)
Source: Roche Media News - February 22, 2013 Category: Pharmaceuticals Source Type: news

FDA approves new treatment for late-stage breast cancer
The U.S. Food and Drug Administration today approved Kadcyla (ado-trastuzumab emtansine), a new therapy for patients with HER2-positive, late-stage (metastatic) breast cancer. (Source: Food and Drug Administration)
Source: Food and Drug Administration - February 22, 2013 Category: American Health Source Type: news

FDA Approves T-DM1 (Kadcyla) for HER2-Positive Breast Cancer
The US Food and Drug Administration approved ado-trastuzumab emtansine (Kadcyla) for the treatment of patients with metastatic HER2-positive breast cancer earlier today. (Source: Cancer Network)
Source: Cancer Network - February 22, 2013 Category: Cancer & Oncology Source Type: news

ImmunoGen, Inc. Announces FDA Approval Of Kadcyla (Ado-Trastuzumab Emtansine; Also Known As T-DM1)
ImmunoGen, Inc ., a biotechnology company that develops anticancer therapeutics using its TAP technology, recently announced that Roche has reported that the U.S. Food and Drug Administration (FDA) has granted marketing approval to Kadcyla for the treatment of people with HER2-positive metastatic breast cancer who have received prior treatment with Herceptin (trastuzumab) and a taxane chemotherapy. (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - February 22, 2013 Category: Pharmaceuticals Source Type: news

FDA Approves Genentech's Kadcyla (Ado-Trastuzumab Emtansine), The First Antibody-Drug Conjugate For Treating HER2-Positive Metastatic Breast Cancer
Genentech, a member of the Roche Group recently announced that the U.S. Food and Drug Administration (FDA) has approved Kadcyla(ado-trastuzumab emtansine or T-DM1) for the treatment of people with HER2-positive metastatic breast cancer (mBC) who have received prior treatment with Herceptin (trastuzumab) and a taxane chemotherapy. (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - February 22, 2013 Category: Pharmaceuticals Source Type: news

Is Lapatinib an Option When Trastuzumab Is Not?Is Lapatinib an Option When Trastuzumab Is Not?
Globally, trastuzumab is not always available for women with HER2+ breast cancer. Dr. Lidia Schapira reports on a study that looks at the potential benefit of oral lapatinib after primary therapy. Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 19, 2013 Category: Consumer Health News Tags: Hematology-Oncology Viewpoint Source Type: news

Dako Receives FDA Approval For Fast, Accurate, Nontoxic FISH Assay For Cancer Diagnostics
Dako, an Agilent Technologies Company, has introduced IQISH technology in the United States. The technology will reduce the turnaround time for cancer evaluation from two days to three and a half hours. This will ease the waiting time and associated anxiety for the patient and allow physicians to more quickly initiate targeted cancer treatments. HER2 IQFISH pharmDx, a fluorescence in situ hybridization (FISH) assay, is the first product approved by the U.S. Food and Drug Administration that uses the Dako IQISH technology, which is based on Dako's fast IQISH hybridization buffer chemistry... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - February 19, 2013 Category: Consumer Health News Tags: Medical Devices / Diagnostics Source Type: news

Draft NICE guidance recommends use of Oncotype DX to guide early breast cancer treatment decisions
Source: NICE Area: News NICE has issued its third diagnostics consultation on gene expression profiling and expanded immunohistochemistry (protein expression profiling) tests to guide the use of adjuvant chemotherapy in early breast cancer management (MammaPrint, Oncotype DX, IHC4 and Mammostrat). These tests measure multiple markers within the tumour that may indicate how the tumour is likely to develop. This third consultation follows consultations on previous drafts and the submission of a confidential access proposal by the manufacturer of Oncotype DX.   The draft guidance recommends the use of Oncotype DX in...
Source: NeLM - News - February 18, 2013 Category: Drugs & Pharmacology Source Type: news

Finding Common Regions of Alteration in Copy Number Data
In this chapter, we review some recent methods designed for detecting recurrent copy number regions, that is, genomic regions that show evidence of being altered in a set of samples. We analyze Affymetrix SNP6 data from 87 Her2-type breast tumors from a recent study using three different methods, showing different definitions and features of common regions: studying heterogeneity in copy number profiles, refining candidates for driver oncogenes, and consolidating broad amplifications. (Source: Springer protocols feed by Genetics/Genomics)
Source: Springer protocols feed by Genetics/Genomics - February 15, 2013 Category: Genetics & Stem Cells Source Type: news

Nonfamilial Breast Cancer Subtypes
Over the last decade, our knowledge in somatic genetic events related to breast cancer has increased ­enormously. Through usage of various genome-wide molecular approaches, it has become increasingly clear that breast cancer is a vastly heterogeneous disease. Microarray-based gene expression profiling has divided breast cancer into five distinct intrinsic subtypes termed basal-like, HER2-enriched, normal-like, luminal A, and luminal B. Importantly, these subtypes are closely correlated to clinical variables as well as different outcomes, with luminal A tumors as the good prognostic group. Initial studies using genome-w...
Source: Springer protocols feed by Genetics/Genomics - February 15, 2013 Category: Genetics & Stem Cells Source Type: news

Diversity of Triple-Negative Breast Cancer Complicates Treatment
Treatment of triple-negative breast cancer, so named because it lacks estrogen receptors, progesterone receptors, and HER2 overexpression, is one of the most challenging areas of breast oncology. Not only... (Source: OncologySTAT Latest News)
Source: OncologySTAT Latest News - February 14, 2013 Category: Cancer & Oncology Source Type: news